Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CooperVision Inc.

Division of Cooper Cos. Inc.
www.coopervision.com

Latest From CooperVision Inc.

Manufacturers Enter The Competitive Online Market For Contact Lenses

Almost one-third of contact-lens patients in the US order lenses online at least some of the time. Manufacturers such as CooperVision are introducing mobile apps that allow them to compete with online-only retailers like 1-800 Contacts.

Ophthalmic Retail

Device/Diagnostics Quarterly Deal-Making Statistics, Q4 2017

Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.

Deals Market Intelligence

Contact Lens Proposals From US Trade Commission To Be Scrutinized This Week

Industry stakeholders say proposed revisions to the US Federal Trade Commission's Contact Lens Rule, including one related to lens substitutions, could create problems for suppliers. The rule will be up for discussion at a March 7 meeting.

Regulation Advertising, Marketing & Sales

Puerto Rico Tax-Haven Status, R&D Credit Weakened By Tax-Reform Bill

Under tax reform legislation recently passed by Congress, a 20% tax on products made in domestic territories will adversely affect the many device firms with Puerto Rican plants that currently enjoy a lower, 4% tax rate on profits. And a second tax provision usually relied upon by medtech companies, the R&D tax credit, also loses ground under the final Senate bill passed Dec. 2.

Legislation Policy & Regulation
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register